A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma
Ahmed Bilal Khalid(Indiana University School of Medicine), Shadia I. Jalal(Indiana University Health), Heather Burney(Indiana University – Purdue University Indianapolis), Hirva Mamdani(Wayne State University), Christos Fountzilas(Roswell Park Comprehensive Cancer Center), Bryan P. Schneider(Shanghai University of Traditional Chinese Medicine), Christopher A. Fausel(Indiana University Health), Susan M. Perkins(Indiana University School of Medicine)
Cited by 4
Related Papers
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
|Clinical Cancer Research|2008|456
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
|The Lancet Oncology|2023|244
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208